total
adult
patient
undergo
endoscop
sinu
surgeri
tertiari
practic
senior
author
rgd
either
cr
access
lesion
prospect
recruit
cr
patient
fulfil
agre
diagnost
criteria
fail
prolong
trial
medic
suffici
extens
diseas
merit
dissect
paranas
sinus
exclus
criteria
normal
sinonas
mucosa
sampl
patient
nonfunct
pituitari
adenoma
patient
malign
lesion
pterygopalatin
fossa
neither
patient
symptom
cr
evid
cr
endoscopi
imag
patient
recruit
southern
hemispher
summer
earli
autumn
month
recruit
ceas
agre
time
previou
year
rate
detect
respiratori
virus
gener
popul
seen
rise
region
ethic
committe
northern
region
ethic
committe
ref
hospit
involv
gave
prior
approv
studi
inform
written
consent
given
patient
patient
demograph
well
relev
past
medic
surgic
histori
record
patient
also
ask
quantifi
long
symptom
nose
sinus
tabl
patient
classifi
basi
presenc
crswnp
absenc
crssnp
nasal
polyp
per
publish
patent
aspirin
exacerb
respiratori
diseas
subject
object
measur
diseas
sever
form
preoper
symptom
record
practic
ask
patient
give
main
symptom
cr
obstruct
anterior
rhinorrhea
posterior
rhinorrhea
hyposmia
midfac
congest
score
base
sever
preced
week
repres
mucos
sampl
collect
ethmoid
sphenoid
sinus
immedi
place
steril
normal
salin
transfer
laboratori
analysi
undertaken
technician
blind
clinic
detail
tissu
piec
approxim
mm
diamet
predigest
proteinas
k
tissu
lysi
buffer
complet
dissolv
roch
high
pure
pcr
templat
prepar
kit
roch
mannheim
germani
extract
use
magna
pure
lc
automat
extractor
total
nucleic
acid
high
perform
kit
accord
manufactur
recommend
total
nucleic
acid
elut
elut
buffer
extract
sampl
yield
averag
nucleic
acid
patient
tissu
piec
process
total
independ
pcr
assay
design
ident
assay
protocol
pcr
platform
includ
influenza
influenza
b
parainfluenza
multiplex
parainfluenza
multiplex
rsv
b
human
metapneumoviru
hmpv
adv
cytomegaloviru
cmv
bocaviru
bov
multiplex
rhinoviru
rv
coronaviru
coronaviru
coronaviru
human
rnasep
act
extract
control
sequenc
adapt
center
diseas
control
prevent
protocol
detect
character
influenza
wwwcdcgov
publish
cmv
assay
design
assay
use
taqman
hydrolysi
probe
label
fluorophor
fam
cal
fluor
orang
end
fluoresc
black
hole
quencher
end
primer
probe
synthes
biosearch
technolog
novato
ca
sequenc
list
tabl
reaction
carri
reaction
mixtur
contain
reaction
mix
invitrogen
ss
iii
platinum
quantit
system
invitrogen
carlsbad
ca
enzym
mix
superscript
iiiplatinum
taq
polymeras
case
adv
cmv
bov
platinum
taq
polymeras
use
forward
revers
primer
fluoresc
probe
extract
ribonucl
acid
rna
dna
pcr
mix
without
enzym
prepar
larg
volum
store
singl
use
aliquot
use
aliquot
pcr
thaw
mix
enzym
aliquot
onto
reaction
plate
rnadna
ad
posit
control
aliquot
last
minim
possibl
contamin
run
contain
templat
control
ntc
water
extract
blank
control
posit
control
posit
control
consist
rna
extract
confirm
tissu
cultur
isol
adv
type
strain
cmv
obtain
commerci
advanc
biotechnolog
columbia
md
bov
control
consist
clone
amplifi
isol
confirm
sequenc
assay
except
bov
subject
annual
qualiti
control
program
distribut
qualiti
control
molecular
diagnost
glasgow
scotland
rcpa
australia
assay
carri
roch
light
cycler
use
micropl
format
amplif
condit
minut
revers
transcript
minut
initi
dna
polymeras
activ
cycl
denatur
second
follow
second
annealingextens
result
analyz
fam
channel
cal
orang
separ
assay
consid
valid
rnasep
amplif
posit
cr
patient
median
durat
symptom
report
year
rang
year
median
preoper
symptom
score
rang
median
score
rang
respiratori
virus
detect
sampl
sinc
convent
respiratori
virus
found
assay
perform
look
virus
known
capabl
establish
persist
infect
name
human
viru
ebv
use
pcr
techniqu
publish
found
sampl
crssnp
patient
crswnp
patient
normal
subject
ebv
found
crssnp
patient
crswnp
patient
normal
subject
low
titer
viru
present
suggest
latent
rather
activ
infect
seem
like
cr
multifactori
pathogenesi
inflammatori
stimuli
differ
differ
stage
diseas
differ
subgroup
respiratori
virus
howev
caus
florid
sinonas
symptom
may
gener
effect
respiratori
mucosa
respiratori
virus
also
shown
capabl
establish
latenc
human
role
respiratori
virus
ongo
inflamm
seen
cr
therefor
warrant
investig
seri
patient
cr
patient
activ
inflamm
despit
use
sensit
test
extens
panel
respiratori
virus
identifi
evid
respiratori
viral
presenc
patient
may
cr
spectrum
diseas
small
sampl
size
may
therefor
includ
variant
clearli
neg
result
suggest
persist
respiratori
viru
infect
respons
chronic
inflamm
seen
major
variant
disord
evid
latent
ebv
infect
seen
cr
mucosa
case
small
number
patient
examin
ebv
found
control
signific
unclear
despit
find
respiratori
virus
seri
note
anim
vitro
model
shown
deleteri
effect
respiratori
viru
infect
may
persist
well
beyond
time
viru
particl
rate
detect
virus
cr
lower
publish
seri
may
part
due
methodolog
differ
collect
sinu
mucosa
rather
inferior
turbin
collect
specimen
summer
month
respiratori
virus
far
less
preval
studi
whether
viral
infect
respons
acut
exacerb
cr
symptom
could
design
similar
fashion
undertaken
winter
month
larg
group
neg
control
patient
would
requir
establish
background
rate
viral
infect
time
year
chronic
natur
cr
impli
present
specialist
care
remot
develop
condit
make
studi
initi
factor
difficult
transient
respiratori
viru
infect
caus
damag
epitheli
surfac
could
process
allow
bacteri
biofilm
form
adher
mucos
surfac
could
caus
chang
inflammatori
milieu
occur
critic
subsequ
develop
cr
found
howev
evid
persist
respiratori
viru
infect
diseas
sinu
mucosa
